![](https://static01.nyt.com/images/2024/05/28/multimedia/28multiplan_senate-gfjh/28multiplan_senate-gfjh-thumbWide.jpg?quality=75&auto=webp&disable=upscale)
Senators See Possible Conflicts of Interest in Health Care Pricing Tools
A data analytics firm that helps insurers collect big fees while leaving some patients with unpaid bills has been summoned to explain its business model.
By Chris Hamby
I focus on unearthing wrongdoing and injustice. Much of my recent work has focused on health care and pharmaceuticals, but I have a range of interests and have written about subjects including labor, criminal justice and international trade. I primarily work on in-depth projects, which often involves digging through troves of documents and speaking with a hundred or more people over many months.
I got my start in journalism covering sports for a small newspaper in Nashville. As a reporter for the nonprofit investigative news outlet the Center for Public Integrity, I won the Pulitzer Prize for investigative reporting in 2014 for exposing how coal companies rigged a compensation system to deny benefits to sick miners. That work grew into the book “Soul Full of Coal Dust,” which was named one of The New York Times’s “100 Notable Books of 2020.” While working at BuzzFeed News, I was a finalist for the Pulitzer Prize in international reporting in 2017 for a series of stories detailing how multinational corporations used a secretive legal tool to strong-arm governments across the globe.
Since joining The Times in 2019, I have written about a politically connected company that strained the nation’s emergency medical stockpile and botched Covid vaccine manufacturing; the unknown role an influential consulting firm played in the opioid crisis; and the risks of growing at-home use of a powerful drug.
A native of Nashville, I earned a bachelor’s degree from the University of Richmond and master’s from the University of Missouri School of Journalism, and I cheer loudly and frequently in vain for the Spiders and Tigers.
Like all Times journalists, I am committed to upholding the standards of integrity outlined in our Ethical Journalism Handbook. I take very seriously my obligations to those who entrust me with sensitive information. I believe that all people, even those accused of serious wrongdoing, deserve fair treatment, and I strive to accurately represent their perspectives. I allow the facts to dictate the story, regardless of where they lead.
I welcome feedback and suggestions for stories. Please contact me by email or direct message to get my phone number, which works with Signal and WhatsApp.
Email: [email protected]
X: @ChrisDHamby
LinkedIn: Chris Hamby
Anonymous tips: nytimes.com/tips
A data analytics firm that helps insurers collect big fees while leaving some patients with unpaid bills has been summoned to explain its business model.
By Chris Hamby
A data analytics firm has helped big health insurers cut payments to doctors, raising concerns about possible price fixing.
By Chris Hamby
Federal regulation capping toxic airborne silica has been decades in the making. The delay has cost miners dearly.
By Chris Hamby
A little-known data firm helps health insurers earn more when less of an out-of-network claim gets paid. Patients can be on the hook for the difference.
By Chris Hamby, Claire Hogan and James Surdam
A private-equity-backed firm has helped drive down payments to medical providers, drive up patients’ bills and earn billions for insurers.
By Chris Hamby
A little-known data firm helps health insurers make more when less of an out-of-network claim gets paid. Patients can be on the hook for the difference.
By Chris Hamby
As medical practices owned by private equity firms fuel overbilling, a payment tool also backed by such investors helps insurers boost their profits.
By Chris Hamby
With loosened rules around remote prescriptions, a psychedelic-like drug has become a popular treatment for mental health conditions. But a boom in at-home use has outpaced evidence of safety.
By Chris Hamby
The consulting firm offered clients “in-depth experience in narcotics,” from poppy fields to pills more powerful than Purdue’s OxyContin.
By Chris Hamby and Michael Forsythe
The report sheds new light on executives’ worries about deficiencies in the company’s quality control systems at its troubled Baltimore plant; no contaminated doses were ever released to the public.
By Sheryl Gay Stolberg, Chris Hamby and Sharon LaFraniere